Although prophylactic treatment with rapamycin decreased HIV-1 susceptibility of epithelial LCs (Fig. 1C), it did not reduce infection of subepithelial CD11c+ DCs or CD4+ T cells (Fig. 2D,F). Here, ITGAX is linked to infection.